Akari Therapeutics (AKTX) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lipocine (LPCN) has outperformed Akari Therapeutics (AKTX) over the past year, losing 53.2% versus a loss of 60.1%. Over five years, LPCN leads with a -92.3% price change compared with -99.5% for AKTX. Akari Therapeutics is the larger company by market cap ($16.7 million vs $16.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | LPCN |
|---|---|---|
| Share price | $7.18 | $1.48 |
| Market cap | $16.70M | $16.39M |
| 1-day change | +7.00% | -1.33% |
| YTD return | -37.89% | -81.57% |
| 1-year return | -60.11% | -53.16% |
| 5-year return | -99.47% | -92.30% |
| EPS (TTM) | $0.00 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.98M |
| Revenue growth (YoY) | — | -82.35% |
| Net income (latest FY) | $-17.30M | $-9.63M |
| Operating margin | — | -524.69% |
| Net margin | — | -487.06% |
| 52-week high | $29.32 | $12.37 |
| 52-week low | $3.02 | $1.36 |
| Distance from 52-week high | -75.51% | -88.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +255.15% | +237.84% |
| Average volume | 58.54K | 1.84M |
| Shares outstanding | 2.33M | 11.07M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
AKTX vs LPCN FAQ
Which is bigger, Akari Therapeutics or Lipocine?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $16.39M for Lipocine (LPCN).
Which stock has performed better over the past year, AKTX or LPCN?
LPCN returned -53.16% over the past 12 months, compared with -60.11% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.